ArticleAntimicrobial agents and chemotherapy2006
Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 311 citations in OpenAlex.
- Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.Journal of the American Heart Association · 2017Trial
- Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial.Intensive care medicine · 2012Trial
- Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa.PLoS pathogens · 2010Trial
- Beyond lethal doses: sub-MIC levels of multi-class antibiotics induce species- and isolate-dependent biofilm inhibition in gram-negative pathogens.BMC microbiology · 2026Article
- A novel stress response pathway mediates biofilm architecture in Pseudomonas aeruginosa.PLoS pathogens · 2026Article
- Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.Probiotics and antimicrobial proteins · 2026Review
- QAL333's antitumor activity and predictive modeling: integrated transcriptomic-bioinformatic analysis reveals selective cytotoxicity and sensitivity determinants.Scientific reports · 2026Article
- Translation quality control in Pseudomonas aeruginosa: current knowledge and perspectives.FEMS microbiology reviews · 2026Review
- Growth-Phase-Dependent Modulation of Quorum Sensing and Virulence Factors inAntibiotics (Basel, Switzerland) · 2025Article
- Novel 1,3,4-oxadiazole-nicotinamide hybrids as non-classical AHL mimics quorum sensing inhibitors of Pseudomonas aeruginosa: design, synthesis and biological evaluation.BMC chemistry · 2025Article
- Inhibition of metallo-β-lactamases in carbapenem resistant Gram negative bacilli by omeprazole and pantoprazole.African health sciences · 2025Article
- Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.npj antimicrobials and resistance · 2025Review
- Antibiotic-ResistantMicroorganisms · 2025Review
- Repurposing antimicrobials with ultrasound-triggered nanoscale systems for targeted biofilm drug delivery.npj antimicrobials and resistance · 2025Article
- Antimicrobial Proficiency of Amlodipine: Investigating its Impact onIndian journal of microbiology · 2025Article
- Reprofiling lamivudine as an antibiofilm and anti-pathogenic agent against Pseudomonas aeruginosa.AMB Express · 2025Article
- Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.Pharmaceutics · 2025Review
- An insight on the powerful of bacterial quorum sensing inhibition.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Review
- Macrolide resistance through uL4 and uL22 ribosomal mutations in Pseudomonas aeruginosa.Nature communications · 2024Article
- Unveiling the synergistic potency of chlorhexidine and azithromycin in combined action.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The administration of macrolides such as azithromycin for chronic pulmonary infection of cystic fibrosis patients has been reported to be of benefit. Although the mechanisms of action remain obscure, anti-inflammatory effects as well as interference of the macrolide with Pseudomonas aeruginosa virulence factor production have been suggested to contribute to an improved clinical outcome. In this study we used a systematic approach and analyzed the impact of azithromycin on the global transcriptional pattern and the protein expression profile of P. aeruginosa PAO1 cultures versus those in untreated controls. The most remarkable result of this study is the finding that azithromycin exhibited extensive quorum-sensing antagonistic activities. In accordance with the inhibition of the quorum-sensing systems, virulence factor production was diminished and the oxidative stress response was impaired, whereas the type III secretion system was strongly induced. Moreover, P. aeruginosa motility was reduced, which probably accounts for the previously observed impaired biofilm formation capabilities of azithromycin-treated cultures. The interference of azithromycin with quorum-sensing-dependent virulence factor production, biofilm formation, and oxidative stress resistance in P. aeruginosa holds great promise for macrolide therapy in cystic fibrosis. Clearly quorum-sensing antagonist macrolides should be paid more attention in the management of chronic P. aeruginosa infections, and as quorum-sensing antagonists, macrolides might gain vital importance for more general application against chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.